Encompass Health Corp (AMEX:EHC) has been given an average recommendation of “Hold” by the fourteen research firms that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $57.78.
Several equities research analysts recently commented on the company. Zacks Investment Research upgraded Encompass Health from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Tuesday, January 30th. Credit Suisse Group assumed coverage on Encompass Health in a report on Wednesday, January 17th. They set an “outperform” rating and a $58.00 target price on the stock. Stephens reiterated a “buy” rating and set a $55.00 target price on shares of Encompass Health in a report on Friday, January 12th. Wells Fargo & Co assumed coverage on Encompass Health in a report on Tuesday, January 30th. They set a “market perform” rating and a $56.00 target price on the stock. Finally, Royal Bank of Canada raised their target price on Encompass Health to $64.00 and gave the company an “outperform” rating in a report on Thursday, March 1st.
Shares of Encompass Health (AMEX EHC) traded up $0.06 during trading hours on Friday, hitting $58.19. The company had a trading volume of 134,745 shares, compared to its average volume of 615,248. The stock has a market cap of $5,720.00, a P/E ratio of 21.47, a P/E/G ratio of 1.70 and a beta of 0.48. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of 1.89. Encompass Health has a 1-year low of $40.86 and a 1-year high of $59.29.
Encompass Health (AMEX:EHC) last announced its earnings results on Monday, February 26th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.64 by $0.06. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Encompass Health had a return on equity of 23.56% and a net margin of 8.67%. The company’s revenue was up 7.3% on a year-over-year basis. During the same period last year, the business posted $0.72 EPS. equities research analysts expect that Encompass Health will post 2.72 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Shareholders of record on Monday, April 2nd will be paid a dividend of $0.25 per share. The ex-dividend date is Thursday, March 29th. This represents a $1.00 dividend on an annualized basis and a yield of 1.72%. Encompass Health’s dividend payout ratio (DPR) is presently 36.90%.
Hedge funds and other institutional investors have recently modified their holdings of the business. FNY Managed Accounts LLC acquired a new stake in Encompass Health during the 4th quarter valued at approximately $125,000. Cerebellum GP LLC acquired a new stake in Encompass Health during the 4th quarter valued at approximately $129,000. Heartland Advisors Inc. acquired a new stake in Encompass Health during the 4th quarter valued at approximately $237,000. Zeke Capital Advisors LLC acquired a new stake in Encompass Health during the 4th quarter valued at approximately $238,000. Finally, S. R. Schill & Associates acquired a new stake in Encompass Health during the 4th quarter valued at approximately $401,000. Hedge funds and other institutional investors own 93.18% of the company’s stock.
About Encompass Health
Encompass Health Corporation, formerly HealthSouth Corporation, is a provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 35 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies.
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.